Casting a New Light on Sepsis Management – Volition Webinar

Volition’s Company Management Dr Retter and Mr Gael Forterre host a webinar.

Dr. Retter will focus on Nu.Q^® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT). Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.

Mr. Forterre will provide an update on Volition’s progress to commercialization through both licensing and direct and indirect sales.